325 related articles for article (PubMed ID: 25481243)
21. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.
Dolatshad H; Pellagatti A; Fernandez-Mercado M; Yip BH; Malcovati L; Attwood M; Przychodzen B; Sahgal N; Kanapin AA; Lockstone H; Scifo L; Vandenberghe P; Papaemmanuil E; Smith CW; Campbell PJ; Ogawa S; Maciejewski JP; Cazzola M; Savage KI; Boultwood J
Leukemia; 2015 May; 29(5):1092-103. PubMed ID: 25428262
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
[TBL] [Abstract][Full Text] [Related]
23. Haploinsufficiency of Sf3b1 leads to compromised stem cell function but not to myelodysplasia.
Matsunawa M; Yamamoto R; Sanada M; Sato-Otsubo A; Shiozawa Y; Yoshida K; Otsu M; Shiraishi Y; Miyano S; Isono K; Koseki H; Nakauchi H; Ogawa S
Leukemia; 2014 Sep; 28(9):1844-50. PubMed ID: 24535406
[TBL] [Abstract][Full Text] [Related]
24. A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts.
Janusz K; Del Rey M; Abáigar M; Collado R; Ivars D; Hernández-Sánchez M; Valiente A; Robledo C; Benito R; Díez-Campelo M; Ramos F; Kohlmann A; Cañizo CD; Hernández-Rivas JM
Leuk Res; 2017 May; 56():82-87. PubMed ID: 28222336
[TBL] [Abstract][Full Text] [Related]
25. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
[TBL] [Abstract][Full Text] [Related]
26. Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome.
Ochi T; Fujiwara T; Ono K; Suzuki C; Nikaido M; Inoue D; Kato H; Onodera K; Ichikawa S; Fukuhara N; Onishi Y; Yokoyama H; Nakamura Y; Harigae H
Sci Rep; 2022 Aug; 12(1):14562. PubMed ID: 36028755
[TBL] [Abstract][Full Text] [Related]
27. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing.
Patnaik MM; Lasho TL; Finke CM; Hanson CA; King RL; Ketterling RP; Gangat N; Tefferi A
Am J Hematol; 2016 May; 91(5):492-8. PubMed ID: 26874914
[TBL] [Abstract][Full Text] [Related]
28. Depletion of Sf3b1 impairs proliferative capacity of hematopoietic stem cells but is not sufficient to induce myelodysplasia.
Wang C; Sashida G; Saraya A; Ishiga R; Koide S; Oshima M; Isono K; Koseki H; Iwama A
Blood; 2014 May; 123(21):3336-43. PubMed ID: 24735968
[TBL] [Abstract][Full Text] [Related]
29. Development of a high-resolution melting analysis for the detection of the SF3B1 mutations.
Yang J; Qian J; Lin J; Yang XF; Qian W; Chen Q; Yao DM; Wang CZ; Chen XX; Xiao GF; Ma YJ
Genet Test Mol Biomarkers; 2013 Apr; 17(4):342-7. PubMed ID: 23390883
[TBL] [Abstract][Full Text] [Related]
30. SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype.
Visconte V; Tabarroki A; Rogers HJ; Hasrouni E; Traina F; Makishima H; Hamilton BK; Liu Y; O'Keefe C; Lichtin A; Horwitz L; Sekeres MA; Hsieh FH; Tiu RV
Haematologica; 2013 Sep; 98(9):e105-7. PubMed ID: 23831919
[No Abstract] [Full Text] [Related]
31. Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron.
Visconte V; Avishai N; Mahfouz R; Tabarroki A; Cowen J; Sharghi-Moshtaghin R; Hitomi M; Rogers HJ; Hasrouni E; Phillips J; Sekeres MA; Heuer AH; Saunthararajah Y; Barnard J; Tiu RV
Leukemia; 2015 Jan; 29(1):188-95. PubMed ID: 24854990
[TBL] [Abstract][Full Text] [Related]
32. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms.
Cazzola M; Rossi M; Malcovati L;
Blood; 2013 Jan; 121(2):260-9. PubMed ID: 23160465
[TBL] [Abstract][Full Text] [Related]
33. Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or
Mortuza S; Chin-Yee B; James TE; Chin-Yee IH; Hedley BD; Ho JM; Saini L; Lazo-Langner A; Schenkel L; Bhai P; Sadikovic B; Keow J; Sangle N; Hsia CC
Curr Oncol; 2024 Mar; 31(4):1762-1773. PubMed ID: 38668037
[TBL] [Abstract][Full Text] [Related]
34. SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution.
Lin CC; Hou HA; Chou WC; Kuo YY; Wu SJ; Liu CY; Chen CY; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Hsu SC; Ko BS; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Aug; 89(8):E109-15. PubMed ID: 24723457
[TBL] [Abstract][Full Text] [Related]
35. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
Patnaik MM; Tefferi A
Am J Hematol; 2021 Mar; 96(3):379-394. PubMed ID: 33428785
[TBL] [Abstract][Full Text] [Related]
36. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.
Chen Z; Wang SA; Goswami M; Tang G; Routbort MJ; Patel KP; Luthra R; Medeiros LJ; Ok CY
Leuk Res; 2019 Nov; 86():106227. PubMed ID: 31557598
[TBL] [Abstract][Full Text] [Related]
37. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.
Papaemmanuil E; Cazzola M; Boultwood J; Malcovati L; Vyas P; Bowen D; Pellagatti A; Wainscoat JS; Hellstrom-Lindberg E; Gambacorti-Passerini C; Godfrey AL; Rapado I; Cvejic A; Rance R; McGee C; Ellis P; Mudie LJ; Stephens PJ; McLaren S; Massie CE; Tarpey PS; Varela I; Nik-Zainal S; Davies HR; Shlien A; Jones D; Raine K; Hinton J; Butler AP; Teague JW; Baxter EJ; Score J; Galli A; Della Porta MG; Travaglino E; Groves M; Tauro S; Munshi NC; Anderson KC; El-Naggar A; Fischer A; Mustonen V; Warren AJ; Cross NC; Green AR; Futreal PA; Stratton MR; Campbell PJ;
N Engl J Med; 2011 Oct; 365(15):1384-95. PubMed ID: 21995386
[TBL] [Abstract][Full Text] [Related]
38. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.
Patnaik MM; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Pardanani A; Tefferi A
Am J Hematol; 2013 Mar; 88(3):201-6. PubMed ID: 23335386
[TBL] [Abstract][Full Text] [Related]
39. [Dyserythropoiesis in myelodysplastic syndrome].
Iwama A
Rinsho Ketsueki; 2018; 59(10):2036-2041. PubMed ID: 30305506
[TBL] [Abstract][Full Text] [Related]
40. Alteration of the SETBP1 gene and splicing pathway genes SF3B1, U2AF1, and SRSF2 in childhood acute myeloid leukemia.
Choi HW; Kim HR; Baek HJ; Kook H; Cho D; Shin JH; Suh SP; Ryang DW; Shin MG
Ann Lab Med; 2015 Jan; 35(1):118-22. PubMed ID: 25553291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
